Case Report
Copyright ©The Author(s) 2021.
World J Clin Cases. May 6, 2021; 9(13): 3219-3226
Published online May 6, 2021. doi: 10.12998/wjcc.v9.i13.3219
Table 1 Evolution of clinical disease activity, laboratory exams, and clinical treatment
Day 1 (at hospital admission)Day 4Day 8Day 15Day 21Day 51After 6 mo
Partial Mayo score (points)9777320
Mayo endoscopic score (points)3-----0
Hematocrit/hemoglobin, (%)/(g/dL)25.8/8.1127.1/8.6135.6/11.934.4/10.832.3/10.628.9/9.440.2/13.8
C-reactive protein (hs-CRP) (< 1.0mg/dL)20.36.02.93.72.7-0.0
Albumin (g/dL)-1.91.92.12.13.54.4
Fecal calprotectin (< 30 μg/g)---921-166-
Infliximab trough level (μg/mL)---8.8> 209.1-
Medical treatmentHydrocortisone 300 mg/d + oral vancomycin 250 mg qidInfliximab 5 mg/kg (first infusion) + hydrocortisone300 mg/dInfliximab 5 mg/kg (second infusion) + hydrocortisone 100 mg/d. Discharge with azathioprine + prednisone 40 mgInfliximab 5 mg/kg + azathioprine (third infusion) + corticosteroid taperingInfliximab 5 mg/kg + azathioprine (fourth infusion) + prednisone 20 mg (dose tapering)Infliximab 5 mg/kg + azathioprine (maintenance treatment)